Anti-PD1 antibodies and their use as therapeutics and diagnostics
AssigneeBeiGene, Ltd.
InventorsKang Li, Tong Zhang, Jing Song, Lanlan Xu, Qi Liu, Hao Peng
Life of this patent
Estimating the term…
Abstract
Provided are antibodies that specifically bind to Programmed Death-1 (PD1, Pdcd-1, or CD279) and inhibit PD1-mediated cellular signaling and activities in immune cells, antibodies binding to a set of amino acid residues required for its ligand binding, and uses of these antibodies to treat or diagnose cancer, infectious diseases or other pathological disorders modulated by PD1-mediated functions.
Claims35
An antibody antigen binding domain which specifically binds human PD-1, and comprises complementarity determining region (CDR) 1, CDR2 and CDR3, in a combination selected from (a)-(r) as follows, wherein the antibody (Ab), heavy chain (HC) or light chain (LC) and CDR nomenclature system (Kabat, IMGT or composite) from which the CDR combinations derive are shown in the first column, and residues in bold text are Kabat system, and residues underlined are IMGT system:
- Ab,
- Chain
- System
- CDR1
- mu317
- GFSLTSYGVH
- HC
- (a)
- Kabat
- SEQ ID NO:
- 11, res. 6-10
- (b)
- IMGT
- SEQ ID NO:
- 11, res. 1-8
- (c)
- Comp.
- SEQ ID NO:
- 11
- mu317
- KASQSVSNDVA
- LC
- (d)
- Kabat
- SEQ ID NO:
- 14-
- (e)
- IMGT
- SEQ ID NO:
- 14, res. 4-9
- (f)
- Comp.
- SEQ ID NO:
- 14
- 317-4B6
- GFSLTSYGVH
- HC
- (g)
- Kabat
- SEQ ID NO:
- 11, res. 6-10
- (h)
- IMGT
- SEQ ID NO:
- 11, res. 1-8
- (i)
- Comp.
- SEQ ID NO:
- 11
- 317-4B6
- KSSESVSNDVA
- LC
- (j)
- Kabat
- SEQ ID NO:
- 34
- (k)
- IMGT
- SEQ ID NO:
- 34, res. 4-9
- (l)
- Comp.
- SEQ ID NO:
- 34
- 317-1H
- GFSLTSYGVH
- HC
- (m)
- Kabat
- SEQ ID NO:
- 11, res. 6-10
- (n)
- IMGT
- SEQ ID NO:
- 11, res. 1-8
- (o)
- Comp.
- SEQ ID NO:
- 11
- 317-4B2
- GFSLTSYGVH
- HC
- (p)
- Kabat
- SEQ ID NO:
- 11, res. 6-10
- (q)
- IMGT
- SEQ ID NO:
- 11, res. 1-8
- (r)
- Comp.
- SEQ ID NO:
- 11
- Ab,
- Chain
- System
- CDR2
- mu317
- VIWAGGSTNYNSALMS
- HC
- (a)
- Kabat
- SEQ ID NO:
- 12
- (b)
- IMGT
- SEQ ID NO:
- 12, res. 2-8
- (c)
- Comp.
- SEQ ID NO:
- 12
- mu317
- YAFHRFT
- LC
- (d)
- Kabat
- SEQ ID NO:
- 15
- (e)
- IMGT
- SEQ ID NO:
- 15, res. 1-3
- (f)
- Comp.
- SEQ ID NO:
- 15
- 317-4B6
- VIYADGSTNYNPSLKS
- HC
- (g)
- Kabat
- SEQ ID NO:
- 32
- (h)
- IMGT
- SEQ ID NO:
- 32, res.2-8
- (i)
- Comp.
- SEQ ID NO:
- 32
- 317-4B6
- YAFHRFT
- LC
- (j)
- Kabat
- SEQ ID NO:
- 15
- (k)
- IMGT
- SEQ ID NO:
- 15, res.1-3
- (l)
- Comp.
- SEQ ID NO:
- 15
- 317-1H
- VIWAGGSTNYNPSLKS
- HC
- (m)
- Kabat
- SEQ ID NO:
- 59
- (n)
- IMGT
- SEQ ID NO:
- 59, res. 2-8
- (o)
- Comp.
- SEQ ID NO:
- 59
- 317-4B2
- VIYAGGSTNYNPSLKS
- HC
- (p)
- Kabat
- SEQ ID NO:
- 60
- (q)
- IMGT
- SEQ ID NO:
- 60, res.2-8
- (r)
- Comp.
- SEQ ID NO:
- 60
- Ab,
- Chain
- System
- CDR3
- mu317
- ARAYGNYWYIDV
- HC
- (a)
- Kabat
- SEQ ID NO:
- 13, res. 3-12
- (b)
- IMGT
- SEQ ID NO:
- 13
- (c)
- Comp.
- SEQ ID NO:
- 13
- mu317
- HQAYSSPYT
- LC
- (d)
- Kabat
- SEQ ID NO:
- 16
- (e)
- IMGT
- SEQ ID NO:
- 16
- (f)
- Comp.
- SEQ ID NO:
- 16
- 317-4B6
- ARAYGNYWYIDV
- HC
- (g)
- Kabat
- SEQ ID NO:
- 13, res. 3-12
- (h)
- IMGT
- SEQ ID NO:
- 13
- (i)
- Comp.
- SEQ ID NO:
- 13
- 317-4B6
- HQAYSSPYT
- LC
- (j)
- Kabat
- SEQ ID NO:
- 16
- (k)
- IMGT
- SEQ ID NO:
- 16
- (l)
- Comp.
- SEQ ID NO:
- 16
- 317-1H
- ARAYGNYWYIDV
- HC
- (m)
- Kabat
- SEQ ID NO:
- 13, res. 3-12
- (n)
- IMGT
- SEQ ID NO:
- 13
- (o)
- Comp.
- SEQ ID NO:
- 13
- 317-4B2
- ARAYGNYWYIDV
- HC
- (p)
- Kabat
- SEQ ID NO:
- 13, res. 3-12
- (q)
- IMGT
- SEQ ID NO:
- 13
- (r)
- Comp.
- SEQ ID NO:
- 13.
Dependencies are inferred from the claim text.